Burning Rock Biotech (NASDAQ:BNR) Sets New 1-Year Low at $17.34

Shares of Burning Rock Biotech Limited (NASDAQ:BNR) hit a new 52-week low during trading on Tuesday . The company traded as low as $17.34 and last traded at $17.46, with a volume of 11882 shares changing hands. The stock had previously closed at $18.38.

A number of equities research analysts have weighed in on the stock. CICC Research started coverage on shares of Burning Rock Biotech in a report on Wednesday, July 14th. They issued an “outperform” rating and a $39.94 price objective on the stock. Zacks Investment Research upgraded Burning Rock Biotech from a “sell” rating to a “hold” rating in a research note on Monday, August 9th.

The company has a 50-day simple moving average of $21.23 and a 200 day simple moving average of $26.02. The company has a market cap of $1.82 billion, a P/E ratio of -19.15 and a beta of -2.13.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Monday, August 30th. The company reported ($1.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($1.82). Burning Rock Biotech had a negative net margin of 134.93% and a negative return on equity of 27.95%. Sell-side analysts predict that Burning Rock Biotech Limited will post -0.79 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in BNR. DekaBank Deutsche Girozentrale bought a new position in shares of Burning Rock Biotech in the 2nd quarter valued at about $772,000. Ensign Peak Advisors Inc bought a new stake in Burning Rock Biotech in the 2nd quarter worth about $90,000. Macquarie Group Ltd. bought a new position in shares of Burning Rock Biotech during the 2nd quarter valued at approximately $95,000. Citigroup Inc. purchased a new stake in Burning Rock Biotech in the 1st quarter worth approximately $98,000. Finally, Asset Management One Co. Ltd. purchased a new position in Burning Rock Biotech in the 2nd quarter worth $125,000. 25.72% of the stock is owned by institutional investors and hedge funds.

Burning Rock Biotech Company Profile (NASDAQ:BNR)

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

Recommended Story: Forex

Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.